Cases reported "Lung Neoplasms"

Filter by keywords:



Filtering documents. Please wait...

1/8. Efficacy of total androgen blockade in metastatic prostatic carcinoma with transient hypogonadotropic hypogonadism: a case report.

    A patient affected by metastatic prostatic carcinoma and hypogonadotropic hypogonadism (HH) was treated with flutamide 750 mg/day plus an LH-RH analog. After confirmation of basal castration during treatment, he continued with antiandrogens alone. Following the normalization of gonadic function and subjective mild bone flare-up, the patient resumed the initial treatment and obtained a partial response. When flutamide was interrupted because of liver toxicity, the patient showed progressive disease in the bone, which was unresponsive to both flutamide resumption and salvage hormone therapy (bicalutamide). The patient is currently receiving chemotherapy with VP16 and estramustine phosphate and is showing both serologic (PSA) and symptomatic response. The interest of this case lies in the incidental detection of HH during therapy and in the responsiveness to treatment.
- - - - - - - - - -
ranking = 1
keywords = castration
(Clic here for more details about this article)

2/8. Failure of buserelin-induced medical castration to control pulmonary lymphangiomyomatosis in two patients.

    Two women, aged 44 and 29 years, respectively, were admitted to the hospital in early 1987 for recurrent pneumothorax, dyspnea and a diffuse reticulonodular pattern evidenced on the chest x-ray film. lung biopsy confirmed LAM in both patients. Both were treated sequentially with medroxyprogesterone and a LHRH agonist (buserelin) to achieve reversible medical castration. Neither subjective nor objective improvement was noted after 13 and 5 months, respectively, of buserelin therapy (900 micrograms/day, nasal spray) despite an effective suppression of the pituitary-gonadal axis. medroxyprogesterone also was ineffective. buserelin thus failed to control pulmonary LAM in these two patients, in spite of effective medical castration.
- - - - - - - - - -
ranking = 6
keywords = castration
(Clic here for more details about this article)

3/8. Use of LHRH analogue to obtain reversible castration in a patient with benign metastasizing leiomyoma.

    The use of superactive LHRH analogue to provide a reversible form of castration is discussed in the context of the management of a patient with benign metastasizing leiomyoma. The aetiology and prognosis of this rare disease are briefly considered.
- - - - - - - - - -
ranking = 5
keywords = castration
(Clic here for more details about this article)

4/8. Utilization of luteinizing hormone-releasing hormone agonist in pulmonary leiomyomatosis.

    A patient presenting a recurrent episode of pulmonary leiomyomatosis has been treated with the LH-RH agonist buserelin at a dosage of 200 micrograms tid SC for 7 days, then 500 micrograms SC daily for a total period of 6 months. Basal serum E2 was suppressed during treatment and varied between 62 and 180 pmol/ml (mean, 129.4 /- 14.5). Pulmonary symptoms completely disappeared during treatment, but no objective regression of the pulmonary lesions was observed. Because of the uncertainty of response of benign metastasizing leiomyomas to castration and because of the reversibility of the medical treatment, LH-RH agonist may be preferred to surgical castration in this pathology.
- - - - - - - - - -
ranking = 2
keywords = castration
(Clic here for more details about this article)

5/8. Radiographic evaluation of treatment of advanced carcinoma of the prostate.

    Radiographic evaluation of 65 patients with disseminated carcinoma of the prostate shows that 8% demonstrated resolution of metastatic deposits after palliative transurethral resection and/or estrogen or castration therapy. The increased effectiveness of therapy and the improved management of patients are reflected in longer survival. Roentgenographic evidence of increasing sclerosis of osteoblastic metastases of carcinoma of the prostate indicates that the rate of bone repair exceeds the rate of bone destruction, and is not necessarily an indication of progression of the disease. Increasing prominence of blastic bony lesions is not a poor prognostic sign; several patients showing it were symptom-free and survived for long periods. Sclerotization of lytic deposits is definitely a good prognostic sign of treatment and represents "healing change" within involved bone.
- - - - - - - - - -
ranking = 1
keywords = castration
(Clic here for more details about this article)

6/8. Pulmonary lymphangiomyomatosis: treatment with castration.

    Pulmonary lymphangiomyomatosis (PLM) is a rare disease of smooth muscle proliferation that generally leads to an early death due to respiratory insufficiency. The disease only affects women. Exacerbations with pregnancy and after hormonal manipulation have been documented. There is presently no successful treatment of the disease. castration as a means of early therapy has been associated with a stable respiratory picture in our patient. Peritoneal-jugular shunt can benefit women with significant ascities.
- - - - - - - - - -
ranking = 4
keywords = castration
(Clic here for more details about this article)

7/8. Response of metastasized sex cord gonadal stromal tumor of the testis to cisplatin-based chemotherapy.

    A 34-year-old man underwent left hemicastration for malignant unclassified sex cord gonadal stromal tumor. At 6 months pulmonary metastases developed and the patient received 3 courses of chemotherapy consisting of cisplatin, bleomycin and etoposide. A residual focus in the right lung was excised and proved to be viable tumor. He then received 2 adjuvant courses of cisplatin, etoposide and ifosfamide. Six months later he was without evidence of disease. A review of the literature revealed 21 previous cases of malignant unclassified sex cord gonadal stromal tumor. Although chemotherapy usually fails in treating Leydig cell tumors our case corroborates 6 previous reports of favorable response to cisplatin-based chemotherapy. This finding suggests that different subtypes of sex cord gonadal stromal tumor respond differently to chemotherapy.
- - - - - - - - - -
ranking = 1
keywords = castration
(Clic here for more details about this article)

8/8. prostate specific antigen and prostate acid phosphatase declines after estramustine phosphate withdrawal: a case report.

    We report a case of advanced prostate cancer in which an initial response to hormonal therapy with surgical castration and estramustine phosphate (EMP) was followed by disease progression, as shown by sequential elevations in serum prostate specific antigen (PSA) and prostate acid phosphatase (PAP) and the development of new symptoms, during maintenance endocrine and anti-cancer chemotherapy. Discontinuation of EMP resulted in sustained reductions in serum PSA and PAP levels and a sustained improvement in symptoms.
- - - - - - - - - -
ranking = 1
keywords = castration
(Clic here for more details about this article)


Leave a message about 'Lung Neoplasms'


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.